Although findings have shown pCR to be a reasonable surrogate for overall survival in triple-negative and HER2+ breast cancer, it is a less appropriate surrogate marker for HR+/HER2– tumors, especially luminal A type tumors.30,31 Therefore, lack of pCR may not have as much influence in the decision to proceed with completion ALND, especially for patients treated with NET who receive only a small proportion of their systemic therapy upfront. This evidence concerns the gene ERBB2 and breast cancer.